These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 33801244)

  • 1. Erb-b2 Receptor Tyrosine Kinase 2 (ERBB2) Promotes ATG12-Dependent Autophagy Contributing to Treatment Resistance of Breast Cancer Cells.
    Chen Y; Wang R; Huang S; Henson ES; Bi J; Gibson SB
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33801244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
    Canfield K; Li J; Wilkins OM; Morrison MM; Ung M; Wells W; Williams CR; Liby KT; Vullhorst D; Buonanno A; Hu H; Schiff R; Cook RS; Kurokawa M
    Cell Cycle; 2015; 14(4):648-55. PubMed ID: 25590338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autophagy facilitates the Lapatinib resistance of HER2 positive breast cancer cells.
    Chen S; Li X; Feng J; Chang Y; Wang Z; Wen A
    Med Hypotheses; 2011 Aug; 77(2):206-8. PubMed ID: 21570197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy.
    Bisaro B; Sciortino M; Colombo S; Camacho Leal MP; Costamagna A; Castellano I; Montemurro F; Rossi V; Valabrega G; Turco E; Defilippi P; Cabodi S
    Oncotarget; 2016 Jan; 7(4):4442-53. PubMed ID: 26716506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
    Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
    Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
    Wang S; Huang X; Lee CK; Liu B
    Oncogene; 2010 Jul; 29(29):4225-36. PubMed ID: 20498641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activated kinase screening identifies the
    Leonardi M; Perna E; Tronnolone S; Colecchia D; Chiariello M
    Autophagy; 2019 Feb; 15(2):312-326. PubMed ID: 30289335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
    Karakashev SV; Reginato MJ
    Oncotarget; 2015 Feb; 6(4):1967-80. PubMed ID: 25596742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autophagy inhibition by TSSC4 (tumor suppressing subtransferable candidate 4) contributes to sustainable cancer cell growth.
    Chen Y; Zhang Z; Henson ES; Cuddihy A; Haigh K; Wang R; Haigh JJ; Gibson SB
    Autophagy; 2022 Jun; 18(6):1274-1296. PubMed ID: 34530675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression.
    Qi L; Zhang B; Zhang S; Ci X; Wu Q; Ma G; Luo A; Fu L; King JL; Nahta R; Dong JT
    Oncotarget; 2017 May; 8(22):36054-36066. PubMed ID: 28415602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ErbB2-dependent downregulation of a pro-apoptotic protein Perp is required for oncogenic transformation of breast epithelial cells.
    Khan IA; Yoo BH; Masson O; Baron S; Corkery D; Dellaire G; Attardi LD; Rosen KV
    Oncogene; 2016 Nov; 35(44):5759-5769. PubMed ID: 27109096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR Family Members' Regulation of Autophagy Is at a Crossroads of Cell Survival and Death in Cancer.
    Henson E; Chen Y; Gibson S
    Cancers (Basel); 2017 Mar; 9(4):. PubMed ID: 28338617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA.
    Xia W; Bacus S; Husain I; Liu L; Zhao S; Liu Z; Moseley MA; Thompson JW; Chen FL; Koch KM; Spector NL
    Mol Cancer Ther; 2010 Feb; 9(2):292-9. PubMed ID: 20124457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib.
    Chen S; Zhu X; Qiao H; Ye M; Lai X; Yu S; Ding L; Wen A; Zhang J
    Tumour Biol; 2016 Feb; 37(2):2321-31. PubMed ID: 26369543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent Autophagy Inhibition Overcomes the Resistance of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Human Bladder Cancer Cells.
    Kang M; Lee KH; Lee HS; Jeong CW; Kwak C; Kim HH; Ku JH
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28165387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells.
    Zhao M; Howard EW; Parris AB; Guo Z; Zhao Q; Ma Z; Xing Y; Liu B; Edgerton SM; Thor AD; Yang X
    Oncotarget; 2017 Aug; 8(35):58847-58864. PubMed ID: 28938602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression.
    Yang W; Klos KS; Zhou X; Yao J; Yang Y; Smith TL; Shi D; Yu D
    Cancer; 2003 Sep; 98(6):1123-30. PubMed ID: 12973835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
    Chu I; Blackwell K; Chen S; Slingerland J
    Cancer Res; 2005 Jan; 65(1):18-25. PubMed ID: 15665275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.